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Modifier screening is a powerful genetic tool. While not widely used in the vertebrate system, we applied these tools to transgenic
mouse strains that recapitulate key aspects of Alzheimer’s disease (AD), such as tau-expressing mice. These are characterized by
a robust pathology including both motor and memory impairment. The phenotype can be modulated by ENU mutagenesis,
which results in novel mutant mouse strains and allows identifying the underlying gene/mutation. Here we discuss this strategy
in detail. We firstly obtained pedigrees that modify the tau-related motor phenotype, with mapping ongoing. We further obtained
transgene-independent motor pedigrees: (i) hyperactive, circling ENU 37 mice with a causal mutation in the Tbx1 gene—the
complete knock-out of Tbx1 models DiGeorge Syndrome; (ii) ENU12/301 mice that show sudden jerky movements and tremor
constantly; they have a causal mutation in the Kcnq1 gene, modelling aspects of the Romano-Ward and Jervell and Lange-Nielsen
syndromes; and (iii) ENU16/069 mice with tremor and hypermetric gait that have a causal mutation in the Mpz (Myelin Protein
Zero) gene, modelling Charcot-Marie-Tooth disease type 1 (CMT1B). Together, we provide evidence for a real potential of an ENU
mutagenesis to dissect motor functions in wild-type and tau mutant mice.
1. Introduction
With an ageing population, Alzheimer’s disease (AD) and
related neurodegenerative disorders represent a serious social
and economic threat to most societies. The cost of caring
for an increasing number of people with dementia continues
to rise. At present, there are an estimated 30 million people
with dementia worldwide, with numbers expected to further
increase to 80 million by 2040. The countries or regions
with the largest numbers of affected individuals are China
and the developing western Pacific, Western Europe, and the
Unites States [1]. The two core histopathological hallmarks
of AD are the amyloid-β (Aβ) plaques and the tau-containing
neurofibrillary tangles (NFTs), both of which have been
described by Alois Alzheimer more than a century ago [2].
Disease-caus-ing mutations in familial cases of AD have
been described two decades ago; yet there is still no cure
for this debilitating disease. The current treatment is lim-
ited to acetylcholine esterase (AChE) inhibitors (donepezil,
rivastigmine, and gal-antamine) and the NMDA receptor
antagonist, memantine; yet neither of these strategies halts
the degenerative process that characterizes AD [3].
What are the characteristics of the major component
of the two hallmark lesions in AD and what causes the
familial cases? The 39–42 amino acid Aβ peptide in the
plaques is fibrillar, as is tau, a microtubule-associated protein
that becomes hyperphosphorylated in the disease process
and eventually aggregates to form NFTs, neuropil threads,
and the abnormal neurites that are associated with some
amyloid-β plaques [4]. Although tau has been generally
perceived as a neuronal protein, with mainly an axonal
localization, we have recently challenged this view by demon-
strating an essential dendritic function under physiological
conditions and in mediating Aβ toxicity [5, 6]. In addition
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to plaques and NFTs, the AD brain is characterized by
massive neuronal cell and synapse loss [7]. Tau pathology,
in the absence of overt Aβ plaques, characterizes a series
of diseases that are collectively known as tauopathies. This
includes FTLD-Tau (frontotemporal lobar degeneration with
tau inclusions) with an inherited form known as FTDP-
17 (frontotemporal dementia with Parkinsonism linked to
chromosome 17). There is a second, major subset of FTLD
characterized by tau-negative yet ubiquitin-positive lesions.
In this subset, the transcription and splicing factor TDP-43
(TAR DNA-binding protein 43) has been identified as the
aggregating protein, and consequently, this form of FTLD has
been named FTLD-TDP [8]. Similar to tau, TDP-43 in the
aggregates is hyperphosphorylated and fragmented, a process
believed to be linked to toxicity [8–11]. Finally, in a third
subset of FTLD, FTLD-FUS, the nuclear protein FUS (Fused-
in-Sarcoma) has been identified as aggregated protein [12].
While both proteins form also aggregates in subsets of
amyotrophic lateral sclerosis (ALS), the mechanisms causing
disease however are believed to differ [13].
The majority of AD cases are sporadic (SAD), with
familial (FAD) cases likely accounting for less than 1%. In
three genes, autosomal dominant mutations have been iden-
tified: amyloid precursor protein (APP), presenilin 1 (PSEN1)
as well as presenilin 2 (PSEN2) [14]. It is the amyloid precur-
sor protein, APP, from which the Aβ peptide is derived by
proteolytic cleavage. Presenilins are components of the mul-
timeric γ-secretase complex that generates Aβ. In addi-tion
to the three FAD genes, apolipoprotein E (APOE) has been
unanimously confirmed as a susceptibility gene in spo-radic
AD (SAD) [14]. More recently, additional risk factor genes
have been identified, with CLU encoding clusterin, PICALM
the phosphatidylinositol-binding clathrin assembly protein,
CR1 the complement component (3b/4b) receptor 1, and
TOMM40 a channel-forming subunit of the translocase of
the mitochondrial outer membrane (TOM) complex [15–
17]. At present, a total of ten genes, mostly with roles in
the immune system and in cholesterol metabolism, are estab-
lished risk genes for AD [18].
Compared to AD, FTLD is a more heterogeneous dis-
order, with variants that are, for example, characterized by
language or behavioural problems [19]. AD and FTLD both
present with a progressive decline of memory function lead-
ing to dementia, although in FTLD this is often preceded by
motor symptoms such as Parkinsonism [20]. It was several
years after the first mutations had been identified in the
APP and PSEN genes in AD, that the first mutations were
identified in a subset of FTLD-Tau, FTDP-17, where they
were found in exonic and intronic sequences of the MAPT
gene that encodes tau [21]. Another subset of familial FTLD
is characterized by mutations in the PGRN gene that en-
codes the pleiotropic protein progranulin, in the VCP gene
that encodes valosin-containing protein, and also in TARDP
encoding TDP-43 [19]; these FTLD-TDP cases are charac-
terized by inclusions of TDP-43 [8]. Finally, mutations in
CHMP2B encoding chromatin modifying protein 2B lead to
FTLD, in the absence of either tau or TDP-43 inclusions [21].
In this paper, we will be discussing a few selected
tau transgenic mouse models with memory and motor
phenotypes and how one of these, the K369I mutant human
tau expressing K3 strain [22], has been employed in an ENU
modifier screen [23], outlining the strategy from breeding to
gene identification.
2. Tau Transgenic Mouse Models with
Memory and Motor Phenotypes
As the focus of this review article is the application of ENU
mutagenesis to one of our mutant tau transgenic mouse
strains, K3, we will be comparing this particular strain with
a few other tau transgenic strains we have established in the
past. Mouse strains that are otherwise available in the field
including those characterized by Aβ plaque formation have
been discussed by us in detail elsewhere [24–27].
What has the ambition been in developing transgenic
mouse strains for the tau pathology of AD in the first
place? The aim has always been to authentically model the
human pathology and to gain a deeper understanding of
what causes tau pathology, how this is related to neurode-
generation and functional impairment, and ultimately, how
pathogenic processes can be prevented or delayed. When
we generated the very first tau transgenic mouse model
in 1995 by expressing the longest human tau isoform in
mice, we reproduced a major aspect of the human pathology
in a subset of neurons: somatodendritic accumulation of
hyperphosphorylated forms of tau, a feature of pathological
tau in AD brains [28]. We failed however to reproduce NFT
formation, neurodegeneration, and functional impairment.
Even by using a stronger promoter to drive human tau
expression, this goal of the early days was not achieved,
although the mice developed a motor phenotype and am-
yotrophy [29, 30].
Only with the identification of pathogenic mutations in
FTLD-Tau in the MAPT gene encoding tau, by expressing
mutant forms such as G272V or P301L tau, we achieved NFT
formation, as determined by Gallyas silver impregnations
and electron microscopy [31, 32]. While we discontinued
the G272V mutant mice [32], the P301L tau transgenic
pR5 strain was employed to provide support for the amy-
loid cascade hypothesis that places Aβ upstream of tau
[33], to reveal behavioural impairments in amygdala- and
hippocampus-dependent tasks [34, 35], to assess the role
of site-specific phosphorylation and in particular of protein
phosphatase 2A (PP2A) in this process [36, 37], to determine
the degree of the cholinergic pathology [38], and to reveal an
impaired stress-related unfolded protein response [39] and a
mitochondrial dysfunction caused by pathological tau [40–
42]. Assessing the role of miRNAs in AD adds an additional
level of complexity [43, 44].
While the pR5 mice display memory impairment as a
major clinical feature of AD, another feature, Parkinsonism,
that characterizes a significant subset of FTLD cases, has been
modelled in K369I mutant tau transgenic K3 mice. We estab-
lished this strain based on the identification of the K369I
mutation of tau in a single patient with Pick’s disease (PiD),
a form of FTLD [45]. As is known for PiD in general, the tau
lesions in the mutation carrier’s brain showed a remarkable
feature when analysed histologically: silver impregnation
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revealed that the tau lesions were Bielschowsky-positive and
Gallyas-negative; moreover, tau was phosphorylated at many
epitopes but not 12E8 (Ser262/Ser356). We succeeded in
reproducing this distinct pathology fully in the K3 mice that
express K369I mutant tau [22]. Memory functions were im-
paired as shown in the novel object recognition test. Owing
to a unique expression pattern of the K369I transgene that
includes the substantia nigra, the K3 transgenic mice also
modelled early-onset Parkinsonism, that is, resting tremor,
bradykinesia, postural instability, and gait anomalies. They
showed an increased cataleptic response to haloperidol and
an early, but not late, response to L-Dopa, indicating that
the dopaminergic system is impaired in these mice. In
recent years, impaired axonal transport has been identified
as a central pathomechanism in AD [46–51]. Conceptually,
impaired axonal transport is linked to oxidative stress and
mitochondrial dysfunction [52]: mitochondria need to be
efficiently transported along the long axonal processes for
neurons to function; furthermore they are a major source
of reactive oxygen species (ROS) [53, 54]. We found a
selectively impaired axonal transport of distinct cargos
including mitochondria and TH- (tyrosine hydroxylase-)
containing vesicles [22]. At the molecular level, we found
that this impaired transport phenotype is due to trapping of
a component of the kinesin motor machinery, the adapter
protein JIP1, by elevated levels of phosphorylated tau,
preventing JIP1 from executing its physiological function in
the axon. A pathological interaction between tau and JIP1
was further revealed in AD and not, control brain, high-
lighting the validity of transgenic animal models in dissecting
pathomechanisms in AD [55]. As tau only traps JIP1 when
it is hyperphosphorylated, this study presents inhibition
of abnormal hyperphosphorylation of tau as a promising
therapeutic strategy in AD [56].
3. Modulation of Transgenic Phenotype by
Therapeutic Intervention
With the pR5 and the K3 mice we do have two comple-
mentary models at hand that present themselves for ther-
apeutic intervention: both strains are characterized by
hyperphosphorylation and increased insolubility of tau as
well as silver-positive inclusions, Gallyas-positive NFTs in the
case of R5 mice [33], and Bielschowsky-positive inclusions
predominantly resembling Pick bodies in K3 mice [22]. The
pR5 mice show an accelerated extinction in the conditioned
taste aversion (CTA) paradigm [34], while the K3 mice have
a memory phenotype as determined by the novel object
recognition test, as well as a motor phenotype that can be
easily monitored either by scoring of clasping, gait, and
tremor (Table 1) or on the Rota-Rod [22, 57]. In addition,
as the K3 mice age, they lose substantial numbers of neurons
both in the substantia nigra (TH-positive neurons) and in
the cerebellum (Basket cells) [22, 57]. Experimental diabetes
exacerbates the tau pathology as shown for pR5 mice [58].
As therapeutic strategies, different approaches can be
envisaged such as the transplantation of cells with the
potential to differentiate in situ either into neuronal or
glial cell types [59]. This strategy has been successfully ap-
plied to mice with a combined tau and Aβ pathology in
which neuronal stem cell transplantation has been shown
to improve cognition via brain-derived neurotrophic factor
(BDNF) [60]. Other strategies that are recently pursued are
tau-based immunizations [61–64]. We used both active and
passive immunization and monitored efficacy of this ap-
proach biochemically, histologically, and behaviourally [65].
We have also been testing a small bioavailable compound,
sodium selenate that can be supplied with the drinking water.
Chronic treatment over a period of four months significantly
improved the pathology in both young and old K3 mice.
The mice showed a gradual improvement on the Rota-Rod
[57]. This was associated with reduced tau hyperphospho-
rylation and decreased numbers of tau inclusions including
spheroids. In fact, spheroids were completely absent from
frontal cortex, suggesting that selenate reverts the functional
impairment leading to spheroids. K3 mice are characterized
by a substantial, age-dependent degeneration of cerebellar
basket neurons, resulting in the absence of pinceau termi-
nals formed by clustered axons surrounding Purkinje cells.
Selenate treatment fully prevented this degeneration as well.
Taken together, these findings show that selenate reduces
tau phosphorylation and deposition, mitigates pathological
spheroid formation, and prevents axonal degeneration of
distinct neuronal populations in K3 mice.
We also treated 8-month-old pR5 mice with sodium
selenate and found that treatment caused a significant im-
pairment in the CTA paradigm. As for the K3 mice, selenate
both caused reduced hyperphosphorylation and numbers
in tau deposits (NFTs) as well as increased tau solubility.
NFT numbers in 12-month-old selenate-treated pR5 mice
were similar to those in 8-month-old-untreated pR5 mice,
suggesting that treatment had halted disease progression.
We further showed that the selenate-induced improvements
require protein phosphatase 2A (PP2A) [57], by performing
in vitro experiments and showing inefficacy of selenate in
mice with a combined tau pathology and reductions in PP2A
activity [66, 67].
4. ENU Mutagenesis Strategies in Mice
While in the AD and ageing field mouse strains are available
with traits that arose spontaneously and have been further
established by specific breeding programs such as the
senescence-accelerated SAM mice [68], the rate at which
new models arise spontaneously means that, even with a
concerted effort, discovery is on an asymptomatic trajectory
towards a phenotype gap [69]. An alternative is random
chemical mutagenesis [69]. The concept of genomewide
mutagenesis is well established in invertebrates such as
the fruit fly Drosophila melanogaster and in the nematode
worm Caenorhabditis elegans, with ENU mutagenesis mainly
producing A to T and T to A transversions [70]. This mu-
tagenesis strategy was used to create the first genetic maps
of Mendelian inheritance in Drosophila, revealing many of
the key genes controlling early embryonic patterning and
development [71]. What makes it possible to carry out
comparable efforts in mice is the extraordinary mutagenic
4 Journal of Biomedicine and Biotechnology
efficiency of ENU in mouse spermatogonial stem cells [72].
By expanding the library of alleles with chemical mutagenesis
using N-ethyl-N-nitosourea (ENU), identification of each of
the single nucleotide changes that result in a particular phe-
notype is feasible in mice and is now providing novel insights
into not only immunity, where this approach has been used
widely [73], but also the functioning of the brain [74].
Genomewide, random mutagenesis with the ethylating
chemical ENU provides a way to produce and screen genetic
variants in the mouse. Intraperitoneal injection of male
founder mice (G0) causes random base pair substitutions in
the DNA of spermatogonial stem cells. Informative muta-
tions are identified by screening members of the pedigrees
propagated from these founders for phenotypes of interest.
Introducing point mutations has the advantage that it most
often inactivates or alters the function of individual protein
domains rather than eliminating the protein altogether (as
is the case for complete knock-outs), making it harder for
related proteins to compensate, better mimicking the effects
of drugs or natural genetic variants, illuminating active
sites in proteins, and revealing specific functions of alter-
natively spliced forms [23]. We have been investigating a
phenotype modulation of our K3 mice by crossing ENU
male founder mice with K3 females as discussed hereinafter.
Here, and in general, dominant mutations are expected to
manifest in the first generation offspring (G1), while re-
cessive mutations are brought to homozygosity in G3 mice
by either G1 × G2 or G2 × G2 crosses [69, 75–80]. The
rate of recessive mutations has been established based on
genotype-driven projects using libraries of G1 gametes gen-
erated from an ENU-treated founder. Sequencing of sentinel
regions of the genome of G1 sperm provides quantitative
and qualitative characteristics of ENU mutagenesis and
information about the probable yield of mutations from
phenotype-driven screens. The consensus is a mutation rate
of 0.5–1.0 mutations/Mbp (7.5 × 10−7 mutations/bp/G0
gamete, or 1500–3000 mutations/G1) from a standard reg-
imen (100 mg/kg/week × 3 for a C57BL/6 founder) [69].
Assuming a 1600 cM 2.6 Gb haploid mouse genome, of
which approximately 1.5% is coding, this comes down
to approximately 50 functional mutations in each G1. Of
these, four will be transmitted to homozygosity in each G3.
The efficiency of ENU-induced mutation means that the
generation of allelic series is highly feasible. Based on a con-
servative estimate of 20 point mutations per G1 gamete,
a survey of 17400 G3s would yield a series of 5 functional
alleles per gene with >99% probability [69].
Limiting factors of the ENU mutagenesis approach are
infertility and lethality, with the standard ENU regimen
resulting in azoospermia (absence of motile sperm in semen)
for up to 10 weeks, with fertility being resumed when the
testes are repopulated by spermatogonia [81]. Persistent in-
fertility on the other hand might occur as a direct conse-
quence of mutagenesis [77]. The presence of mutations that
confer lethality before weaning sets the workable upper limit
of the ENU dose even more stringently. For example, one
study found that 1/13 G1 mice contained lethal mutations
in the balancer chromosome 11 region that contains 5% of
the genome, with the consequence that 18% of the G3 pop-
ulation will not survive because of lethal mutations [77].
For phenotype-driven strategies (such as a motor phe-
notype, see the following), F1 and F3 mice are examined
for dominant-acting and recessive-acting mutations, respec-
tively [23, 82]. The recovery rate of dominant mutations is
low (2%) [83]; on the other hand however, costs for iden-
tifying recessive mutations are much higher, due to much
higher mouse numbers and sample size to be screened and
sequenced. In an ideal screen, the phenotypes are qualtitative
(such as having a motor phenotype) or binomial (rejection
of transplanted tissue or not); they are free of false positives
and are sufficiently penetrant to permit meiotic mapping.
The latter is typically achieved first by outcrossing and
then an F1 intercrossing to yield F2 mice; 50 F2 mice are
required to obtain a 10 Mb mapping resolution with a 95%
confidence [84], although haplotype mapping might enable
an estimation of the chromosomal location using as few as 10
affected F2 mice [85]. For a more detailed discussion of the
likelihood of a confounding mutation cosegregating with the
phenotype the reader is referred to two excellent reviews on
the topic [23, 69].
5. ENU Mutagenesis Applied to K3
Mice Identifies Transgene-Dependent
and -Independent Pedigrees
Applying ENU mutagenesis to mice with neurological phe-
notypes is quite novel. What makes the approach feasible
is a simple read-out, and in this respect, motor phenotypes
are much easier to monitor than memory phenotypes. As
in our K3 mice, K369I mutant tau expression causes both a
motor and memory impairment [22], changes to the motor
phenotype by any intervention although interesting in itself
can also serve as a surrogate marker for changes in memory
functions. We initiated an ENU mutagenesis program in K3
mice that generated transgene-dependent and -independent
pedigrees. In the following we will be discussing five pedi-
grees, ENU164 (partial rescue, transgene-related), ENU67
(slow weight gain, transgene-related), ENU37 (circling,
not transgene-related), ENU12/30a (motor phenotype, not
transgene-related), and ENU16/069 (motor phenotype, not
transgene-related).
To first establish that the K3 phenotype is fully pene-
trant on the background chosen for ENU mutagenesis, we
established backcrosses with 20 mice each, using C57BL/10,
C3H/H3H, FVB, C57Led, and BALB/b mice, all of which are
established ENU strains at the APF (Australian Phenomics
Facility, Canberra). We decided to use BALB/b as the strain
for ENU mutagenesis, as the K3 phenotype of Parkinsonism
is fully penetrant on this background, both with regards
to phenotype and age-of-onset. Therefore, BALB/b males
were injected with ENU and paired with the K3 mice (that
are on a C57BL/6 background), and the F1 offspring was
analyzed. The litters born were scored for three read-outs of
Parkinsonism in mice, tremor (staging 0–3), gait anomalies
(staging 0–3), limb clasping (staging 0–5), as well as body
weight (Table 1).
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Table 1: Phenotyping protocol for ENU/K3 mice. Four phenotypes are being scored, limb clasping, tremor, and gait abnormalities (cardinal
features defining Parkinsonism) and body weight.
(1) Limb clasping
Procedure: → Lift the mice by the tail just so much above the grid, that they try to reach it with their front paws. Keep the mice in this
position for at least 30 seconds. Should the phenotype not be obvious, touch hind limbs? This will ensure that clasping becomes obvious
Stage Definition
0 No clasping (wild-type phenotype)
1 Short and transient clasping only after stimulation (grabbing of grid or touching of hind limbs)
2 Persistent hind limb clasping after stimulation (grabbing of grid or touching of hind limbs)
3 Spontaneous hind limb clasping without major stimulation (when lifted for a few seconds by the tail)
4 Spontaneous clasping of hind- and fore limbs
5 Clasping of hind- or fore limbs persists for more than 5 sec after mice have been placed back into the home cage
(2) Tremor
Procedure: → Observe mice in home cage
Stage Definition
0 No tremor (wild-type)
1 Intermitted mild tremor
2 Continuous mild tremor
3 Continuous intensive tremor
(3) Gait anomalies
Procedure: → Place mice on metal surface in the sterile hood. Ensure that surface between cages is clean. Observe gait and posture
Stage Definition
0 Normal gait, normal posture (wild-type)
1 Intermittendly shaking gait, normal posture
2 Shaking gait, spreading of hind limbs, flattening of the rear body part
3 Continuously shaking gait, spreading of hind limbs, postural instability, dragging of rear body
(4) Body weight
Procedure: → Weigh mouse on the same balance in the same container. Record two digits after the comma
Schedule
Procedure: → First analysis at 4 weeks of age, with follow-ups every week until x weeks of age
We had previously phenotyped wild-type BALB/b mice
for the three Parkinsonism characteristics and weight.
Although none of them displayed abnormal gait or resting
tremor, 37% did clasp their hind limbs when stimulated and
5% clasped their hind limbs without stimulation, while their
front paws grasped the cage wire. Therefore, to ensure accu-
rate identification of the phenotype, the hindlimb clasping
alone was not used as sole indicator, but in conjunction
with tremor and abnormal gait. Genotyping was done by
PCR. Phenotyping was done at weaning, and then at one-
week intervals until around 8 weeks of age, depending on the
scoring outcome. Any mice exhibiting all three phenotypes
and genotyped K3-tau positive were culled, as were any
mice failing to display any of the phenotypes and genotyped
K3-tau negative. Mice which showed a genotype/phenotype
mismatch were genotyped a second time for confirmation
and phenotyped for up to 3 months. Any mice which did
not display the phenotype until after 5 weeks of age were also
noted as having delayed onset of the phenotype and were
flagged as a putant (potential mutant) of interest. Putants
were then bred to F3 by crossing the ENU strains to B6
twice. This was followed by Next Generation whole exome
sequencing as a means to identifying mutations.
We would like to make the comment that while, previ-
ously, we have been mapping the ENU mutations down to a
chromosomal region for most strains these days it is much
faster to directly “next generation sequence” the exomes of
one to two affected mice instead. This has greatly accelerated
the speed of discovery from years to months and reduced
costs of identifying causal mutations. For a recent review
on next generation sequencing (NGS) see [86]. The SNPs
identified with the sequencing were then validated against
the phenotype with an Amplifluor SNP assay for each SNP.
This identified only the causal mutation as it directly relates
to the phenotype.
Hereinafter we will be discussing five pedigrees for which
we have arrived at different stages of out-crossing and
identification of the underlying gene mutations, starting with
those pedigrees with which we have the least progressed.
ENU164 Pedigree. This pedigree is characterized by a partial
rescue of the Parkinsonism phenotype that characterizes
the K3 mice, because some transgene-positive mice in the
pedigree showed an improvement in our vigorous weekly
scorings; for example, at week 6 they would show a scoring
of 1/2/1 for gait/clasp/tremor instead of 3/4/3 as is typical for
6 Journal of Biomedicine and Biotechnology
K3 mice. As mentioned above, consecutive backcrossing onto
C57BL/6 reduces the number of “functional” ENU-induced
point mutations such that in the 3rd generation (F3) they
are reduced to 3-4 mutations. As the K3 mice have been gen-
erated on a C57BL/6 background, while ENU mutagenesis
has been on a BALB/b inbred genetic background, strain-
specific SNP detection enabled the genomic mapping of
the causative mutation location on the BALB/b background.
This narrows down the linked mutation-carrying region to
less than 20 Mb, at which point candidate genes in the region
will be sequenced to detect mutant alleles, and eventually,
the causative mutation. So far, we screened 39 K3-positive
F2s obtained from Founder F1.164. 6 of these showed
the inherited partial rescue phenotype (∼15% inheritance).
From F2 #483 we screened 11 K3-positive mice, with 3
showing partial rescue (∼27%), from F2 #430 20 K3-positive
mice (∼35%). Exome (NGS) next generation sequencing is
ongoing to identify the one single gene mutation that causes
the K3 modulating phenotype.
ENU67 Pedigree. This pedigree shows a worsening of the
weight phenotype that characterises the K3 mice. For
example, while the average weight of transgene-negative mice
is 19,0 grams at six weeks of age, this is reduced to 15.8
grams for transgene-positive K3 mice and is even further
reduced in the ENU67 pedigree (K3-positive) that shows an
average weight of only 11.7 grams. F1.67 had 4 offspring,
with 2 K3-positive mice. Both K3-positive mice (#347, #350)
were identified as slow to gain weight, and we are currently
crossing further to determine the underlying gene mutation.
ENU37 Pedigree. These mice are hyperactive and display
an intermittent circling in both directions. Some of the
mice show head tilting and weaving. The trait shows
Mendelian inheritance over three generations. Following
deep sequencing of the exome of 2 affected mice we identified
possible causal point mutations in the following genes:
(i) 5730455P16Rik (RIKEN cDNA);
(ii) tcof1 (Treacher Collins Franceschetti syndrome 1),
responsible for the production of treacle, which plays
a role in the formation of tissue in the face. The
human disease is also autosomal dominant;
(iii) Tbx1 (T-Box 1 gene) T-box genes encode tran-
scription factors involved in the regulation of
developmental processes. Chromosomal deletions in
this region have been linked to neural-crest-related
defects. A point mutation could potentially cause a
mild neural phenotype;
(iv) Senp7 (SUMO1/sentrin specific peptidase 7 gene)
involved in the posttranslational modification of
proteins by the addition of ubiquitin-like SUMO
proteins;
(v) Ggt7 (gamma-glutamyltransferase 7 gene): this gene
is a member of a family that encodes enzymes
involved in both the metabolism of glutathione and
in the transpeptidation of amino acids; changes
in the activity of γ-glutamyltransferase may signal
preneoplastic or toxic conditions in the liver or
kidney in humans;
(vi) Hkdc1 (hexokinase domain containing 1 gene);
(vii) Chrna4 (cholinergic receptor, nicotinic, alpha
polypeptide 4 Gene): this gene encodes a nicotinic
acetylcholine receptor. Mutations cause nocturnal
frontal lobe epilepsy type 1. Polymorphisms in this
gene provide protection against nicotine addiction in
humans.
Amplifluor primers were designed to the above SNPs and
affected and unaffected mice genotyped, which led to the
confirmation of the causal mutation in the Tbx1 gene,
with a T to A substitution of bp 857 (coding position)
resulting in an Asn to Ile change of amino acid 276. A
complete knock-out of Tbx1 is available and is a model
of DiGeorge Syndrome; it is further characterized by peri-
natal death [87, 88]. The DiGeorge syndrome is caused
by a 1.5 to 3.0 Mb hemizygous deletion of chromosome
22q11.2. Haploinsufficiency of the Tbx1 gene in particular
is responsible for most of the physical malformations.
There is evidence that point mutations in the TBX1 gene
can also cause the disorder. DiGeorge syndrome is the
most frequent microdeletion syndrome in humans, and is
characterized by cardiovascular, thymic and parathyroid, and
craniofacial anomalies. The underlying cause is disturbed
formation of the pharyngeal apparatus, a transient structure
present during vertebrate development that gives rise to
endocrine glands, craniofacial tissue, and the cardiac outflow
tract. The pharyngeal apparatus is composed of derivatives
of ectoderm, endoderm, mesoderm, and the neural crest.
Thus, complex interactions between cell types from different
origins have to be orchestrated in the correct spatiotemporal
manner to establish proper formation of the pharyngeal sys-
tem. The analysis of engineered mouse mutants developing
a phenotype resembling DiGeorge syndrome has revealed
genes and signalling pathways crucial for this process.
Intriguingly, these mouse models reveal that interference
with either of two distinct phases of pharyngeal apparatus
development can contribute to the aetiology of DiGeorge
syndrome [89]. With regards to AD, Tbx1 has been shown
to be upregulated when mice are injected with Aβ [90].
Furthermore, String 9.0 Known and Predicted Protein-Protein
Interactions for Tbx1 identify Sept5 which is also among 29
genes that are deregulated in pR5 tau transgenic mice (JG
and LIM, manuscript submitted). The value of the ENU37
strain lies in the absence of a perinatal phenotype which
allows for studies which are not feasible with the complete
knockout.
ENU12/301 Pedigree (in Short: ENU12). ENU12 mice, under
mild stress, show sudden jerky movements when moving
around the cage and appear to tremor constantly. They often
toss their heads upwards. Some mice show what could be
described as opisthotonus (a type of spasm in which the head
and heels arch backwards in extreme hyperextension and the
body forms a reverse bow). The mice display varying degrees
of severity; even when severely affected, they are able to move
Journal of Biomedicine and Biotechnology 7
freely and quickly around the cage. They occasionally fall to
either side and circle around the cage in very fast movements
when highly stressed, such as when the cage is changed. There
is no preference in a single mouse to circle in either direction.
The ENU12 phenotype can be recognised at weaning.
Deep sequencing identified an A to T substitution of
bp 1408 in exon 10 of the Kcnq1 gene that results in a Lys
to STOP change of amino acid 435. Aliases of KCNQ1 are
KCNA9, KVLQT1, AW559127, and Kv7.1. The KCNQ1 gene
encodes a voltage-gated potassium channel protein required
for the repolarisation phase of the cardiac action potential.
The gene product can form multimers with two other po-
tassium channel proteins, KCNE1 and KCNE3. In-herited
forms of a human condition known as Long QT syn-drome
(LQTS), an abnormality in the cardiac ventricular repo-
larisation characterised by QT interval prolongation and
abnormal T-waves on an electrocardiogram (ECG), are most
commonly associated with mutations in KCQN1. Some pa-
tients show only a cardiac defect (Romano-Ward sy-ndrome,
RWS, dominant); others may suffer from severe deafness
due to a lack of endolymph in the vestibular and auditory
compartment (Jervell and Lange-Nielsen syndrome, JLNS,
recessive) [91].
The complete knockout is a model of JNLS [92], but
the mice show an additional circling (shaker/waltzer) and
rapid head blobbing phenotype. Introducing the familial
A340E point mutation by a knock-in approach models RWS
(cardiac phenotype, but no inner ear defect) [93]. This
point mutation is in the amino-terminus of KCNQ1 that
contains the six transmembrane domains S1-S6 and the pore
domain P [94]. A comparative analysis of the strains al-
lowed the authors to draw conclusions with regards to the
etiology of the cardiac phenotype. How does the ENU12
strain differ from the above two models? The K434Stop mu-
tation in the ENU12 mice is in the carboxy-terminus that
contains four helical regions, of which two form coiled-
coil assemblies. The carboxy-terminus constitutively binds
the calcium sensor, calmodulin [94]. The mutation removes
three helices, essentially abrogating calmodulin binding. The
ENU12 strain has a phenotype similar to the complete
knock-out demonstrating an essential role for the helical do-
main in KCNQ1 function.
ENU16/069 Pedigree (in Short: ENU16). With minimal
stress, ENU16 mice display a mild action tremor. With
moderate stress the tremor worsens and the mice display an
unusual, hypermetric gait in their hind limbs. Upon restrain-
ing of the tail either one or both hind limbs show dramatic
“clasping”, and when returned to the cage, it takes some time
for the mice to regain control over the limbs with what looks
to be a sporadic and short-term lack of control of the hind
limbs. Within seconds of being returned to the cage post
restraint the gait appears to improve but can persist and
be quite unsteady and “waddle-like”. The phenotype is no-
ticeable from 4 to 5 weeks of age.
Deep sequencing identified an A to G substitution of bp
530 in exon 5 of the Mpz (Myelin Protein Zero) gene resulting
in an Asp to Gly change of aa 121. Aliases of MPZ are MPP,
P-zero, and P0, among others. Schwann cells, the glia of
the peripheral nervous system (PNS), play pivotal roles in
the development and maintenance of the PNS. In addition
to forming the myelin sheath, Schwann cells are involved
in neuronal survival where they also provide support to
axons during development and throughout adulthood. The
Mpz gene encodes a transmembrane glycoprotein that is
the major structural protein of peripheral myelin. Muta-
tions in the Mpz gene result in the autosomal dominant
form of Charcot-Marie-Tooth disease type 1 (CMT1B)
[95]. Over 120 point mutations have been identified in
humans until today (http://www.molgen.ua.ac.be/CMTMu-
tations/Mutation/Default.cfm). The structure of the extracel-
lular domain of P0 resembles an immunoglobulin variable
domain. This domain is important for the homotypic
interactions that convey the self-adhesive properties that are
essential to maintain myelin compaction and integrity [96].
The complete P0 knockout causes a severe demyeli-
nating neuropathy [96], but the function of P0 is still
not fully resolved [97]. The mice are deficient in normal
motor coordination and exhibit tremors and occasional
convulsions. Axons in their peripheral nerves are severely
hypomyelinated, and a subset contain myelin-like figures and
axons degenerate. A second strain is available from Jackson
Laboratories: B6.Cg-Mpzttrr/GrsrJ mice carry the sponta-
neous totterer mutation. The underlying gene mutation has
not been reported. Homozygous mice are poor breeders, re-
producing at most once or twice, and as females are poor
mothers, use of the strain is limited. There are also transgenic
strains available that overexpress CMT1B mutant forms of
Mpz [98]. How does the ENU16 strain differ from available
mutant strains? Besides the totterer strain, for P0 there is
only a complete knock-out available, and not a knock-in
strain. The ENU16 strain has an N121G point mutation that
is juxtaposed to the only known glycosylation site in the
protein. We found however by immunohistochemistry and
Western blot analysis that the mutated protein (P0 N121G) is
expressed at a pattern and at levels similar to wild-type. This
allows us to employ the ENU16 strain in studies (such as of
adhesion) that are not feasible with the complete knockout.
6. Outlook
This overview of pedigrees with motor phenotypes reveals
that mice are amenable to ENU mutagenesis and that it is
possible to establish interesting phenotypes. Compared to
the functional genomics approaches we have pursued in the
past [99–102], ENU mutagenesis is more directed as it not
only identifies gene mutations that modulate an existing
pathology but also has the added advantage of establishing
mutant mouse strains at the same time. As outlined above,
ENU tends to introduce point mutations rather than causing
deletions; this results in the expression of mutant proteins
at levels that are high enough to perform functional studies.
A limitation in a more wide-spread application of ENU
mutagenesis though to mice is the high costs associated with
establishing the mutants and identifying the underlying gene
mutation and the fact that not all phenotypes are amenable
to a robust and fast read-out. Therefore, using the motor
phenotype as a surrogate marker for memory functions (as
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for the K3 transgene-dependent pedigrees) is an avenue that
can be pursued in the field of AD mouse models.
What are the challenges of ENU mutagenesis in trans-
genic models of neurodegeneration and what issues both
practical and conceptual did we encounter while doing
these studies? In hindsight it appears to have been the pre-
ferred strategy to start with as many ENU-mutagenised
males for cross-breeding with K3 mice as possible in order
to saturate the genome with mutations. Also, we had ini-
tially planned to identify both dominant and recessive muta-
tions, but considering the extensive breeding needed, we
realised that such an undertaking is not affordable and there-
fore we concentrated solely on dominantly inherited traits.
In principle however recessive mutations would be very
interesting to work with.
The question that may be raised is which other trans-
genic models could be easily screened and used for ENU
mutagenesis. We believe that any strain with a phenotype
that can be easily picked up is amenable to this strategy. In
our case we have been using mice that are characterized by
a robust tau-dependent motor and memory phenotype, so
we assumed that any modification of the motor phenotype
would also modify memory functions, a trait, which would
be tested after the modification of the motor phenotype has
been confirmed. Another question is what the expectations
are beyond finding possible new targets and how we see the
field evolving in the years ahead. We have started to establish
Caenorhabditis elegans in the laboratory as a system comple-
mentary to mice and it seems that overall a mutagenesis
screen in the roundworm system is easier. We still believe that
there is a potential in applying ENU mutagenesis to mouse
models. These models might nicely complement ongoing
concerted efforts such as those of the International Knockout
Mouse Consortium (http://www.knockoutmouse.org/). The
main objectives of this consortium are to generate, archive,
and distribute worldwide up to 12.000 conditional mutations
across the mouse genome in mouse embryonic stem (ES)
cells. Another goal is to establish a limited number of
mouse mutants from this resource. The main mutagenesis
strategies pursued are: (i) conditional gene trapping—a ran-
dom approach for expressed genes; (ii) conditional-targeted
trapping—a directed approach, used for expressed genes;
and (iii) conditional gene targeting—a directed approach,
used for non-expressed genes
Hopefully, these concerted efforts help in developing a
cure for a disease for which only symptomatic treatment is
available [1].
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teracts with c-Jun N-terminal kinase-interacting protein 1
(JIP1) in Alzheimer disease,” Journal of Biological Chemistry,
vol. 284, no. 31, pp. 20909–20916, 2009.
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